ArticleCell transplantation
Extracellular vesicles from melatonin-preconditioned mesenchymal stromal cells protect human umbilical vein endothelial cells against hypoxia/reoxygenation detected by UHPLC-QE-MS/MS untargeted metabolic profiling.
Article in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolomics-guided Mechanisms of Mesenchymal Stromal Cell and Exosome Therapies in Chronic Diseases.Stem cell reviews and reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial ischemia-reperfusion injury (MIRI), which occurs when the blood supply is restored in the ischemic myocardium, is a major medical concern for patients with acute myocardial infarction (AMI). Despite the use of extracellular vesicles (EVs) from mesenchymal stromal cells (MSCs), which can be used to treat MIRI, the application of EVs still has limited use in clinical practice. Melatonin (MT), however, not only exerts a significant protective effect in the treatment of cardiovascular diseases but also enhances biological functions of MSCs through pretreatment. Therefore, in the current study, we sought to determine whether MT improves the paracrine effect of MSCs through pretreatment. Our research provides evidence to support the therapeutic effect of MT-pretreated MSCs-derived extracellular vesicles (MT-EVs) in ameliorating hypoxia/reoxygenation (H/R) injury in human umbilical vein endothelial cells (HuVECs). We also performed a metabolomic analysis using ultra-high-performance liquid chromatography/Q Exactive HF-X Hybrid Quadrupole-Orbitrap Mass (UHPLC-QE-MS/MS) to explore metabolism profiling of H/R cell model with MT-EVs or EVs from MSCs (NC-EVs) treatment. We found 932 differential metabolites (DEMs) in the MT-EVs group compared with the NC-EVs group. Metabolic profiling analysis showed these metabolites were engaged in the ABC transporters, nucleotide metabolism, purine metabolic pathway, and glycerophospholipid metabolism. Furthermore, we observed increased levels of palmitoylcarnitine (fatty acid-derived mitochondrial substrate) and gabapentin in the MT-EVs group, which may play a therapeutic role in HuVECs during H/R. In conclusion, the results demonstrated that MT-EVs can protect endothelial cells from H/R injury by affecting the metabolic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.